Assembly Biosciences, Inc. (NASDAQ:ASMB) Forecasted to Post Q1 2024 Earnings of ($2.74) Per Share

Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Assembly Biosciences in a research note issued on Monday, April 1st. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will post earnings of ($2.74) per share for the quarter. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($14.77) per share. HC Wainwright also issued estimates for Assembly Biosciences' Q2 2024 earnings at ($2.96) EPS, Q3 2024 earnings at ($3.29) EPS, Q4 2024 earnings at ($3.66) EPS, FY2024 earnings at ($12.65) EPS, FY2025 earnings at ($13.45) EPS, FY2026 earnings at ($14.31) EPS and FY2027 earnings at ($15.22) EPS.

Separately, StockNews.com cut Assembly Biosciences from a "hold" rating to a "sell" rating in a research note on Thursday, March 28th.

Assembly Biosciences Trading Up 2.1 %

Shares of NASDAQ ASMB traded up $0.29 during midday trading on Wednesday, hitting $13.79. 41,105 shares of the company's stock were exchanged, compared to its average volume of 29,818. The company has a market cap of $75.57 million, a price-to-earnings ratio of -0.81 and a beta of 0.57. Assembly Biosciences has a 12-month low of $7.69 and a 12-month high of $20.04. The business's fifty day moving average price is $12.33 and its two-hundred day moving average price is $10.64.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of Assembly Biosciences in the first quarter worth approximately $27,000. Tower Research Capital LLC TRC raised its position in Assembly Biosciences by 110.2% in the third quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 8,992 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Assembly Biosciences by 15,633.0% in the 1st quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 14,695 shares in the last quarter. UBS Group AG raised its holdings in Assembly Biosciences by 110.0% in the 4th quarter. UBS Group AG now owns 24,007 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 12,576 shares during the period. Finally, Two Sigma Investments LP purchased a new position in Assembly Biosciences during the first quarter valued at $32,000. Institutional investors own 19.92% of the company's stock.

Insider Buying and Selling at Assembly Biosciences

In related news, major shareholder Alexander Schornstein purchased 24,999 shares of the company's stock in a transaction dated Wednesday, January 17th. The shares were purchased at an average price of $9.36 per share, with a total value of $233,990.64. Following the acquisition, the insider now directly owns 655,357 shares in the company, valued at approximately $6,134,141.52. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 2,066 shares of company stock worth $26,924. Insiders own 4.10% of the company's stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.